Predicting Success of Phase III Trials in Oncology
Stephan Hegge, Markus Thunecke, Matthias Krings, Léonard Ruedin, Jan Saputra Müller, Paul von Bünau
doi: https://doi.org/10.1101/2020.12.15.20248240
Stephan Hegge
1Hegge Holding UG, Kopernikusstr. 24, 10247 Berlin
Markus Thunecke
2Catenion GmbH, Münzstrasse 18, 10278 Berlin, Germany
Matthias Krings
2Catenion GmbH, Münzstrasse 18, 10278 Berlin, Germany
Léonard Ruedin
3idalab GmbH, Potsdamer Straße 68, 10785 Berlin, Germany
Jan Saputra Müller
4AskBy GmbH, Boxhagener Str. 18, 10245 Berlin
Paul von Bünau
3idalab GmbH, Potsdamer Straße 68, 10785 Berlin, Germany

Data Availability
All data used to create this document are referenced and available at links below.
Posted December 16, 2020.
Predicting Success of Phase III Trials in Oncology
Stephan Hegge, Markus Thunecke, Matthias Krings, Léonard Ruedin, Jan Saputra Müller, Paul von Bünau
medRxiv 2020.12.15.20248240; doi: https://doi.org/10.1101/2020.12.15.20248240
Subject Area
Subject Areas
- Addiction Medicine (62)
- Allergy and Immunology (142)
- Anesthesia (44)
- Cardiovascular Medicine (408)
- Dermatology (47)
- Emergency Medicine (141)
- Epidemiology (4809)
- Gastroenterology (177)
- Geriatric Medicine (70)
- Health Economics (187)
- Health Informatics (621)
- Health Policy (314)
- Hematology (85)
- HIV/AIDS (155)
- Medical Education (91)
- Medical Ethics (24)
- Nephrology (73)
- Neurology (677)
- Nursing (41)
- Nutrition (110)
- Oncology (438)
- Ophthalmology (138)
- Orthopedics (36)
- Otolaryngology (88)
- Pain Medicine (35)
- Palliative Medicine (15)
- Pathology (127)
- Pediatrics (193)
- Public and Global Health (1798)
- Radiology and Imaging (321)
- Respiratory Medicine (255)
- Rheumatology (86)
- Sports Medicine (61)
- Surgery (100)
- Toxicology (23)
- Transplantation (28)
- Urology (37)